2020 Market Spotlight on Tuberculosis (TB) - Licensing and Asset Acquisition Deals - ResearchAndMarkets.com

The "Market Spotlight: Tuberculosis (TB)" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.

Key Takeaways

• The publisher estimates that in 2018, there were 13.9 million incident cases of tuberculosis (TB) worldwide, and forecasts that number to increase to 15.3 million incident cases by 2027.
• Approved drugs in the TB space focus on a variety of targets. The majority of these drugs are administered via the oral route, with the remainder being topical and intravenous formulations.
• The majority of industry-sponsored drugs in active clinical development for TB are in Phase II. Therapies in mid-to-late-stage development for TB focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with the remainder being tested in intramuscular and intradermal formulations.
• High-impact upcoming events for drugs in the TB space comprise topline Phase II trial results for GSK3036656 and a meeting with the FDA for SPR720.
• The overall likelihood of approval of a Phase I antibacterial, mycobacterial, or fungal asset is 24.3%, and the average probability a drug advances from Phase III is 62.6%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.
• There have been 17 licensing and asset acquisition deals involving TB drugs during 2015-20. The largest deal was the $74.5m transaction agreement in 2018 between Evotec and Sanofi, pursuant to which Evotec will integrate Sanofi's infectious disease unit into its organization and in-license the majority of Sanofi's infectious disease research portfolio, including TB.
• The distribution of clinical trials across Phase I-IV indicates that the majority of trials for TB have been in the early and midphases of development, with 75% of trials in Phase I-II, and only 25% in Phase III-IV.
• South Africa has a substantial lead in the number of TB clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia
• Clinical trial activity in the TB space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for TB, with 17 trials.
• GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for TB.

Key Topics Covered:

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

• Disease definition
• Patient subtypes
• Symptoms
• Risk factors
• Diagnosis

TREATMENT

• Anti-tuberculosis drugs
• Surgery

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

• Pretomanid for TB (June 6, 2019)
• Pretomanid for TB (June 4, 2019)
• Pretomanid for TB (April 18, 2019)
• Pretomanid for TB (October 26, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

• Mylan Gets Expert Panel Go-Ahead For Pretomanid In India
• Global Approvals Snapshot: November 2019
• Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions
• Pretomanid Gets Panel Endorsement As Part Of Regimen, Not Individual Molecule, For Treatment-Resistant TB

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

• Pfizer Deal Covers Sutezolid For TB
• Deals Shaping The Medical Industry, December 2019
• Shionogi, Hsiri Expand Mycobacterial R&D Pact
• BioNTech Gets Gates Foundation Funding For HIV, TB Drug Discovery

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE

• Sponsors by status
• Sponsors by phase
• Recent events

BIBLIOGRAPHY

• Prescription information

APPENDIX

Companies Mentioned

• GlaxoSmithKline
• Sanofi
• Evotec
  
  

For more information about this report visit https://www.researchandmarkets.com/r/6jyfh5

View source version on businesswire.com: https://www.businesswire.com/news/home/20200703005084/en/